Literature DB >> 13679446

Telomerase reactivation is an early event in laryngeal carcinogenesis.

Bostjan Luzar1, Mario Poljak, Irena J Marin, Nina Gale.   

Abstract

The exact role and timing of reactivation of telomerase, a key enzyme implicated in cellular immortalization and transformation in the multistep process of laryngeal carcinogenesis, is still unknown. We attempted to (1) determine that quantitative differences exist in the levels of telomerase catalytic subunit (hTERT) mRNA expression among different grades of laryngeal epithelial abnormalities classified according to the Ljubljana classification; (2) determine that telomerase reactivation is an important, most probably early event in laryngeal carcinogenesis; and (3) analyze whether the relative quantity of hTERT mRNA can be used as a molecular biomarker in the early detection of precancerous lesions. The relative quantity of hTERT mRNA, expressed as an hTERT index, was analyzed in 140 frozen laryngeal tissue specimens representing different morphological stages of laryngeal carcinogenesis by using a commercially available LightCycler Telo TAGGG hTERT Quantification kit. The presence and relative quantity of hTERT mRNA in laryngeal epithelium increases progressively with the degree of epithelial abnormalities. hTERT mRNA was detectable in 1/15 normal laryngeal epithelia (7%, mean hTERT index 0.02), 3/15 simple hyperplasias (20%, mean hTERT index 0.09), 10/27 abnormal hyperplasias (37%, mean hTERT index 0.18), 9/12 atypical hyperplasias (75%, mean hTERT index 0.74), 8/9 intraepithelial carcinomas (89%, mean hTERT index 1.82), and 53/62 invasive laryngeal squamous cell carcinomas (85%, mean hTERT index 2.51). Statistical analysis revealed two groups of laryngeal epithelial changes with significant differences in the levels of hTERT mRNA expression (P <.0033): (1) normal and reactive hyperplastic laryngeal epithelium (simple and abnormal hyperplasia) and (2) atypical hyperplasia (precancerous lesion), intraepithelial and invasive laryngeal squamous cell carcinoma. The results of the present study suggest that telomerase reactivation is an early event in laryngeal carcinogenesis, detectable already at the stage of precancerous laryngeal epithelial changes. Nevertheless, other genetic abnormalities appear to be necessary for progression of these epithelial abnormalities toward invasive laryngeal squamous cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13679446     DOI: 10.1097/01.MP.0000086488.36623.27

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  5 in total

1.  Effects of cadmium on telomerase activity, expressions of TERT, c-myc and P53, and apoptosis of rat hepatocytes.

Authors:  Wentao Dai; Huajie Chen; Rian Yu; Lingfei He; Bing Chen; Xuemin Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-12-22

Review 2.  Oral premalignant lesions: from the pathological viewpoint.

Authors:  Toshiyuki Izumo
Journal:  Int J Clin Oncol       Date:  2011-01-14       Impact factor: 3.402

3.  Human telomerase RNA component (hTERC) gene amplification detected by FISH in precancerous lesions and carcinoma of the larynx.

Authors:  Yu Liu; Xiao-li Dong; Cheng Tian; Hong-gang Liu
Journal:  Diagn Pathol       Date:  2012-03-30       Impact factor: 2.644

4.  Expression of human telomerase reverse transcriptase protein in oral epithelial dysplasia and oral squamous cell carcinoma: An immunohistochemical study.

Authors:  Bangalore Nagarajachar Raghunandan; Karpagaselvi Sanjai; Jayalakshmi Kumaraswamy; Lokesh Papaiah; Bhavna Pandey; Bellur MadhavaRao Jyothi
Journal:  J Oral Maxillofac Pathol       Date:  2016 Jan-Apr

Review 5.  Telomeres and telomerase in head and neck squamous cell carcinoma: from pathogenesis to clinical implications.

Authors:  Paolo Boscolo-Rizzo; Maria Cristina Da Mosto; Enrica Rampazzo; Silvia Giunco; Annarosa Del Mistro; Anna Menegaldo; Lorena Baboci; Monica Mantovani; Giancarlo Tirelli; Anita De Rossi
Journal:  Cancer Metastasis Rev       Date:  2016-09       Impact factor: 9.264

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.